已收盘 12-15 16:00:00 美东时间
0.000
0.00%
FACTBOX-US energy sector deals regain momentum after mid-2025 slowdown Updates lede, adds Coterra-Devon merger and 2025 deals Feb 2 (Reuters) - Dea lmaking in the U.S. oil and gas sector saw a slowdown in the middle of 2025, but eventually gained momentum in the fourth quarter , with upstream deals
02-03 01:47
US upstream M&A market rebounds in Q4, hits $23.5 billion, Enverus says Jan 28 (Reuters) - The U.S. upstream mergers and acquisitions market regained momentum after a mid-year slowdown in the fourth quarter of 2025 reaching $23.5 billion in announced deals and pushing full-year activity to $65 billi
01-28 22:30
Vital Energy ( ($TSE:VUX) ) has shared an announcement. Vital Energy Inc. has a...
01-06 11:07
Dec 15 (Reuters) - Crescent Energy Co CRGY.N: CRESCENT ENERGY CLOSES TRANSFORMATIVE ACQUISITION OF VITAL ENERGY Source text: ID:nBw7LyM5Ra Further company coverage: CRGY.N ((Reuters.Briefs@thomsonreut...
2025-12-15 23:56
At a special meeting, Vital Energy stockholders approved the merger with Crescent Energy, anticipated to close on December 15, 2025. Vital Energy stockholders will receive 1.9062 shares of Crescent’s Class A common stock for each share held. Trading of Vital Energy common stock on NYSE will cease on December 15. The merger aims to create a larger, financially robust entity with enhanced scale and cash flow generation capabilities, benefiting all ...
2025-12-12 21:20
Vital Energy ( ($VTLE) ) just unveiled an update. Vital Energy, Inc. entered in...
2025-12-06 06:49
Dec 1 (Reuters) - Crescent Energy Co CRGY.N: CRESCENT ENERGY ANNOUNCES EXCHANGE OFFERS AND CONSENT SOLICITATIONS FOR VITAL ENERGY, INC.’S 7.75% SENIOR NOTES DUE 2029 AND 9.750% SENIOR NOTES DUE 2030 S...
2025-12-01 21:46
Crescent Energy Co., through its subsidiary Crescent Energy Finance LLC, has launched exchange offers and consent solicitations for Vital Energy, Inc.'s outstanding 7.75% Senior Notes due 2029 and 9.7...
2025-12-01 21:01
今日重点评级关注:Oppenheimer:维持Olema Pharmaceuticals"跑赢大市"评级,目标价从22美元升至45美元;Bernstein:维持Atlassian"跑赢大市"评级,目标价从290美元升至304美元
2025-11-19 11:01
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从12美元升至15美元;Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从106美元升至107美元
2025-11-13 09:58